Mounjaro, Ozempic, Wegovy, and Saxenda: What the Clinical Trials Measured
Exercise professional · creator of the Letz method

Short answer
Ozempic and Wegovy are brand names for semaglutide; Mounjaro and Zepbound, for tirzepatide; Saxenda and Victoza, for liraglutide. In phase 3 trials, semaglutide and tirzepatide produced average weight losses of around 15% to over 20% of body weight over 68 to 72 weeks, always alongside intensive lifestyle intervention.
Brand and active ingredient
The most common confusion is treating a brand name as if it were a molecule. Semaglutide is sold as Ozempic and Wegovy; tirzepatide, as Mounjaro and Zepbound; liraglutide, as Saxenda and Victoza. The differences between brands of the same active ingredient lie in the approved indication and presentation, not in a different substance.
Scientific literature typically identifies the active ingredient. Even so, a finding with semaglutide does not automatically apply to every brand, dose, or indication: the population, presentation, and dosing regimen studied must accompany the interpretation.
What the trials recorded
In the cited trials involving adults with obesity, semaglutide and tirzepatide produced average weight losses of around 15% to over 20% over 68 to 72 weeks. These numbers reflect the specific populations and regimens studied, not every individual who uses one of these brands.
One detail of these study designs rarely makes the headlines: every trial included intensive lifestyle intervention alongside the medication. The published figure reflects drug therapy combined with structured support, not the medication in isolation.
Liraglutide appears in the literature with smaller magnitude, and the most notable trial for people who train combined supervised exercise with the medication: the combination outperformed both medication alone and exercise alone in sustaining weight loss and reducing body fat.
What the trials do not answer
They do not answer which medication is best for you. Head-to-head comparisons between molecules are limited, populations differ, and the choice depends on clinical details—comorbidities, tolerance, history—that belong with your physician, not in a paper.
Nor do they adequately answer questions about body composition. The primary endpoint was total body weight, and the breakdown between fat and lean mass comes from secondary analyses and reviews, which carry less precision than the headline weight figure suggests.
And they do not answer what happens afterward. That is what extension trials are for, measuring weight regain after discontinuation—reading them is just as essential as reviewing the primary trials.
Frequently asked questions
What is the difference between Ozempic and Wegovy?
They are brand names for the same active ingredient, semaglutide, with different approved indications and presentations. The choice between them is clinical and rests with the prescribing physician.
Does Mounjaro cause more weight loss than Ozempic?
Tirzepatide trials reported average weight losses in the upper range of published data, while semaglutide trials reported figures around 15%. Direct head-to-head comparisons between both molecules are limited, and study populations and trial designs differ—meaning these results cannot be treated as a definitive ranking.
Did these studies include diet and exercise?
Yes. All cited phase 3 trials included intensive lifestyle intervention alongside the medication. The published outcomes reflect that combination.
Registry rules cited here
- GLP-1: Lean Mass and Regain After DiscontinuationTrials observed substantial weight loss, with some reduction in lean mass. In the STEP 1 extension, weight regain followed withdrawal of both semaglutide and lifestyle support. Supervised exercise was studied with liraglutide.
- Nutritional Support During GLP-1 TreatmentMonitoring should prioritize symptoms, nutritional adequacy, protein, resistance training, and preserving lean mass and function.
Sources cited
- Wilding et al., New England Journal of Medicine, 2021 DOI 10.1056/NEJMoa2032183
- Wilding et al., Diabetes, Obesity and Metabolism, 2022 DOI 10.1111/dom.14725
- Jastreboff et al., New England Journal of Medicine, 2022 DOI 10.1056/NEJMoa2206038
- Lundgren et al., New England Journal of Medicine, 2021 DOI 10.1056/NEJMoa2028198
- Neeland et al., Diabetes, Obesity and Metabolism, 2024 DOI 10.1111/dom.15728
- Mozaffarian et al., American Journal of Clinical Nutrition, 2025 DOI 10.1016/j.ajcnut.2025.04.023
- Almandoz et al., Obesity, 2024 DOI 10.1002/oby.24067
- Sievenpiper et al., Obesity Pillars, 2026 DOI 10.1016/j.obpill.2025.100228
Informational content about training and nutrition. It is not a recommendation, prescription or adjustment of any medication, and it does not replace assessment by your doctor or dietitian.